Definitive Healthcare (NASDAQ:DH) Stock Rating Upgraded by Wall Street Zen

Definitive Healthcare (NASDAQ:DH) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Sunday, Wall Street Zen reports.

Other equities analysts have also issued reports about the stock. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $1.00 target price on shares of Definitive Healthcare in a report on Wednesday, August 12th. Morgan Stanley reduced their price target on shares of Definitive Healthcare from $2.50 to $1.50 and set an “equal weight” rating on the stock in a research report on Tuesday, August 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Definitive Healthcare in a research note on Monday, August 31st. BTIG Research restated a “neutral” rating on shares of Definitive Healthcare in a research report on Friday, September 4th. Finally, Bank of America restated an “underperform” rating and set a $0.70 target price on shares of Definitive Healthcare in a research note on Monday, June 29th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, Definitive Healthcare currently has a consensus rating of “Reduce” and an average target price of $1.47.

Definitive Healthcare Stock Down 2.9%

Shares of DH opened at $1.02 on Friday. Definitive Healthcare has a 12 month low of $0.61 and a 12 month high of $4.35. The firm’s 50 day moving average is $0.79 and its 200-day moving average is $0.91. The stock has a market capitalization of $108.89 million, a PE ratio of -0.64, a P/E/G ratio of 12.96 and a beta of 1.40. The company has a current ratio of 1.86, a quick ratio of 1.86 and a debt-to-equity ratio of 0.81.

Definitive Healthcare (NASDAQ:DH) last issued its quarterly earnings results on Monday, August 10th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.01. Definitive Healthcare had a positive return on equity of 3.55% and a negative net margin of 72.28%.The business had revenue of $55.20 million during the quarter, compared to analysts’ expectations of $55.47 million. Definitive Healthcare has set its FY 2026 guidance at 0.180-0.200 EPS and its Q3 2026 guidance at 0.040-0.050 EPS. Equities research analysts forecast that Definitive Healthcare will post 0.06 EPS for the current year.

Institutional Trading of Definitive Healthcare

Several hedge funds and other institutional investors have recently made changes to their positions in DH. Squarepoint Ops LLC grew its holdings in Definitive Healthcare by 46.5% during the 2nd quarter. Squarepoint Ops LLC now owns 351,575 shares of the company’s stock worth $292,000 after acquiring an additional 111,634 shares during the last quarter. Corient Private Wealth LP acquired a new position in Definitive Healthcare in the 2nd quarter valued at approximately $378,000. Williams & Novak LLC raised its stake in shares of Definitive Healthcare by 155.8% during the second quarter. Williams & Novak LLC now owns 78,610 shares of the company’s stock valued at $65,000 after acquiring an additional 47,880 shares during the last quarter. Irenic Capital Management LP bought a new position in shares of Definitive Healthcare during the first quarter valued at $71,000. Finally, Flywheel Private Wealth LLC acquired a new position in shares of Definitive Healthcare during the first quarter worth $83,000. 98.67% of the stock is currently owned by institutional investors.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.